2022
Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma
Eugster PJ, Maurer J, Vocat C, Abid K, Matter M, Wuerzner G, Trepp R, Fischli S, Henzen C, Kolb W, Bilz S, Sigrist S, Beuschlein F, Nölting S, Reul A, Schütze I, Hubers SA, Brown NJ, Grouzmann E. Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. Clinica Chimica Acta 2022, 534: 146-155. PMID: 35905838, DOI: 10.1016/j.cca.2022.07.018.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Gland NeoplasmsHealthy VolunteersHumansMetanephrineNeuropeptide YParagangliomaPheochromocytomaProtein PrecursorsTandem Mass SpectrometryConceptsUpper reference limitPlasma free metanephrinesNeuropeptide YSevere kidney impairmentFree metanephrinesNPY3-36Kidney impairmentSympathetic nervesCatecholamine reuptakeVasoconstrictor peptideNPY2-36NPY1-36Early diagnosisHealthy volunteersPPGL patientsAdrenal medullaTumor localizationPatientsNPYReference limitsDiagnostic sensitivityPPGLsGold standardReference intervalsPheochromocytoma
2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS
Vocat C, Dunand M, Hubers SA, Bourdillon N, Millet G, Brown NJ, Wuerzner G, Grouzmann E, Eugster PJ. Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry 2019, 92: 859-866. PMID: 31790196, PMCID: PMC8541045, DOI: 10.1021/acs.analchem.9b03505.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ImmobilizedChromatography, High Pressure LiquidEquipment DesignHumansLimit of DetectionNeuropeptide YSolid Phase ExtractionTandem Mass SpectrometryConceptsNeuropeptide YNPY3-36Hypertensive patientsHealthy volunteersConcentrations of NPYEndogenous neuropeptide YHuman plasmaNPY2-36Pathological processesReference intervalsEndogenous peptidesChromatography-tandem mass spectrometryPatientsAcid peptideMS/MSVolunteersMetabolitesInter-assay precisionPeptidesPrototype peptideTandem mass spectrometryDistinct effectsOrthostasisCatecholaminesSubpicomolar concentrations
2017
Two Pools of Epoxyeicosatrienoic Acids in Humans
Elijovich F, Milne GL, Brown NJ, Laniado-Schwartzman M, Laffer CL. Two Pools of Epoxyeicosatrienoic Acids in Humans. Hypertension 2017, 71: 346-355. PMID: 29279315, PMCID: PMC5764817, DOI: 10.1161/hypertensionaha.117.10392.Peer-Reviewed Original ResearchConceptsSalt-resistant subjectsDihydroxyeicosatrienoic acidsEpoxyeicosatrienoic acidsBlood pressurePlasma epoxyeicosatrienoic acidsRegulation of natriuresisSalt-sensitive subjectsUrine sodium excretionPotential therapeutic implicationsRenal poolSodium excretionInpatient protocolNormotensive subjectsFractional excretionVascular dysfunctionVascular toneSystemic originTherapeutic implicationsTotal poolNatriuresisSalt loadingExcretionUrine poolsAldosteroneCatecholamines
2013
An LC–MS assay for the screening of cardiovascular medications in human samples
Dias E, Hachey B, McNaughton C, Nian H, Yu C, Straka B, Brown NJ, Caprioli RM. An LC–MS assay for the screening of cardiovascular medications in human samples. Journal Of Chromatography B 2013, 937: 44-53. PMID: 24013190, PMCID: PMC3800555, DOI: 10.1016/j.jchromb.2013.08.010.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular AgentsChromatography, LiquidDrug MonitoringHumansLimit of DetectionLinear ModelsReproducibility of ResultsTandem Mass SpectrometryConceptsAngiotensin II receptor blockersDrug metabolitesCardiovascular drugsDrug classesHospitalized patientsSingle LC-MS/MS methodLC-MS assayLC-MS/MS methodII receptor blockersCalcium channel blockersCardiovascular drug classesClinical samplesDrug detectionSpiked samplesMS methodCardiovascular medicationsReceptor blockersBeta blockersMedication administrationChannel blockersEnzyme inhibitorsClinical settingBlockersDrugsSimultaneous analysis